
Join to View Full Profile
1544 Newton CourtDavis, CA 95618
Phone+1 530-754-6975
Dr. Gray is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Board-certified psychiatrist and neuroscientist at UC Davis and the Associate Director of the Institute for Psychedelics and Neurotherapeutics.
My laboratory studies the molecular and cellular mechanisms involved in synapse function and plasticity, how these processes are disrupted in neurological and psychiatric disorders, and therapeutic approaches that selectively modify synapse strength in specific circuits. Our work is primarily focused on the regulation of NMDA and 5-HT2A receptors.
Education & Training
- University of California (San Francisco)Residency, Psychiatry, 2005 - 2009
- Case Western Reserve University School of MedicineClass of 2005
Certifications & Licensure
- CA State Medical License 2006 - 2026
- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- Graduate Program Advising and Mentoring Award UC Davis, 2024
- Distinguished Alumni Award UCSF Psychiatry Residency, 2019
- Travel Fellowship Award Society of Biological Psychiatry, 2013
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsd-Serine Inhibits Non-ionotropic NMDA Receptor Signaling.Eden V Barragan, Margarita Anisimova, Vishnu Vijayakumar, Azariah Coblentz, Deborah K Park
The Journal of Neuroscience. 2024-08-07 - 4 citationsD-serine availability modulates prefrontal cortex inhibitory interneuron development and circuit maturation.Oluwarotimi O Folorunso, Stephanie E Brown, Jugajyoti Baruah, Theresa L Harvey, Shekib A Jami
Scientific Reports. 2023-06-13 - 6 citationsGluN3A subunit tunes NMDA receptor synaptic trafficking and content during postnatal brain development.Inmaculada M González-González, John A Gray, Joana Ferreira, María Jose Conde-Dusman, Delphine Bouchet
Cell Reports. 2023-05-30
Journal Articles
- When clozapine is not enough. Augment with lamotrigine?Gray JA, Risch SC, Current Psychiatry
- Developing selectively non-selective drugs for treating CNS disorders.Gray JA, Roth BL, Drug Discovery Today: Therapeutic Strategies
Books/Book Chapters
Abstracts/Posters
- Novel molecular replacement strategy for dissecting synaptic and extrasynaptic NMDA receptor targeting.Gray JA, Sanz-Clemente A, Roche KW, Nicoll RA, Federation of European Neuroscience Societies Annual Meeting, Barcelona, Spain
- CaMKII binding to GluN2B controls synaptic NMDAR composition by facilitating the phosphorylation of the GluN2B PDZ ligandSanz-Clemente A, Gray JA, Ogilvie KA, Nicoll RA, Roche KW, for Neuroscience, New Orleans, LA
- Distinct modes of AMPA receptor suppression at developing synapses by the NMDA receptor subunits GluN2A and GluN2B.Gray JA, Usui H, During MJ, Sakimura K, Nicoll RA, Society for Neuroscience, Washington DC
- Join now to see all
Grant Support
- K08 Research Career Development AwardNational Institute of Mental Health2013–Present
- NARSAD Young Investigator AwardBrain & Behavior Research Foundation2010–2012
Professional Memberships
- Member
- California Psychiatric AssociationMember
- Northern California Psychiatric SocietyMember
- Society for NeuroscienceMember
External Links
- ORCiDhttps://orcid.org/0000-0002-7287-0748
- Psychedelicshttps://neurotherapeutics.ucdavis.edu/
- LinkedInhttps://www.linkedin.com/in/john-a-gray-md-phd-a832a823/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: